# Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection

> **NCT04308278** · PHASE4 · RECRUITING · sponsor: **Labo'Life** · enrollment: 88 (estimated)

## Conditions studied

- EBV Infection

## Interventions

- **DRUG:** 2LEBV® / 2LXFS®
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04308278
- **Lead sponsor:** Labo'Life
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2021-01-22
- **Primary completion:** 2026-08-22
- **Final completion:** 2026-08-30
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2024-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04308278

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04308278, "Study to Evaluate the Efficacy of 2LEBV® and 2LXFS® on Asthenia in Patients With an Epstein-Barr Virus Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04308278. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*